381 related articles for article (PubMed ID: 33830022)
1. Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products.
Auletta JJ; Novakovich JL; Stritesky GL; Newman J; Fridy-Chesser ST; Hailperin K; Devine SM
Transplant Cell Ther; 2021 Feb; 27(2):133-141. PubMed ID: 33830022
[TBL] [Abstract][Full Text] [Related]
2. Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program.
Farhadfar N; Newman J; Novakovich J; Barten J; Ndifon ET; Oakes J; Cody M; Pham HP; Auletta JJ; Miller JP; Devine SM; Stefanski HE
Front Immunol; 2022; 13():937900. PubMed ID: 36203566
[TBL] [Abstract][Full Text] [Related]
3. Demand and usage of unrelated donor products for allogeneic haematopoietic cell transplantation during the COVID-19 pandemic: A Canadian Blood Services Stem Cell Registry analysis.
Allan DS; Green M; Morris G; Weiss J; Dibdin N; Mercer D; Seftel M
Vox Sang; 2022 Sep; 117(9):1121-1125. PubMed ID: 35583125
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.
Hsu JW; Farhadfar N; Murthy H; Logan BR; Bo-Subait S; Frey N; Goldstein SC; Horowitz MM; Lazarus H; Schwanke JD; Shah NN; Spellman SR; Switzer GE; Devine SM; Shaw BE; Wingard JR
Transplant Cell Ther; 2021 Jun; 27(6):507-516. PubMed ID: 33865804
[TBL] [Abstract][Full Text] [Related]
5. Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor.
Fingerson S; Maiers M; Bolon YT; Devine SM; Spellman SR
Blood Adv; 2024 Feb; 8(3):758-765. PubMed ID: 38127270
[TBL] [Abstract][Full Text] [Related]
6. Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program.
Pidala J; Mupfudze TG; Payton T; Barker J; Perales MA; Shaw BE; Fernández-Viña M; Burns LJ; Dehn J
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2501-2506. PubMed ID: 31419569
[TBL] [Abstract][Full Text] [Related]
7. Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation.
Fingrut WB; Davis E; Archer A; Brown S; Devlin S; Nhaissi M; Rapoport C; Chinapen S; Kelly A; Wells D; Scaradavou A; Gyurkocza B; Papadopoulos E; Politikos I; Shaffer BC; Barker JN
Blood Adv; 2024 Jun; 8(11):2753-2764. PubMed ID: 38429097
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.
Kumar AJ; Kim S; Hemmer MT; Arora M; Spellman SR; Pidala JA; Couriel DR; Alousi AM; Aljurf MD; Cahn JY; Cairo MS; Cutler CS; Farhan S; Gergis U; Hale GA; Hashmi SK; Inamoto Y; Kamble RT; Kharfan-Dabaja MA; MacMillan ML; Marks DI; Nakasone H; Norkin M; Qayed M; Ringden O; Schouten HC; Schultz KR; Solh MM; Teshima T; Urbano-Ispizua A; Verdonck LF; Gale RP; Hamilton BK; Majhail NS; Loren AW
Blood Adv; 2018 May; 2(9):1022-1031. PubMed ID: 29739773
[TBL] [Abstract][Full Text] [Related]
9. Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program.
Kanda Y; Inoue M; Uchida N; Onishi Y; Kamata R; Kotaki M; Kobayashi R; Tanaka J; Fukuda T; Fujii N; Miyamura K; Mori SI; Mori Y; Morishima Y; Yabe H; Kodera Y
Transplant Cell Ther; 2021 Aug; 27(8):664.e1-664.e6. PubMed ID: 33964514
[TBL] [Abstract][Full Text] [Related]
10. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
[TBL] [Abstract][Full Text] [Related]
11. The National Marrow Donor Program: improving access to hematopoietic cell transplantation.
Walker T; Milford E; Chell J; Maiers M; Confer D
Clin Transpl; 2011; ():55-62. PubMed ID: 22755401
[TBL] [Abstract][Full Text] [Related]
12. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR.
Dehn J; Spellman S; Hurley CK; Shaw BE; Barker JN; Burns LJ; Confer DL; Eapen M; Fernandez-Vina M; Hartzman R; Maiers M; Marino SR; Mueller C; Perales MA; Rajalingam R; Pidala J
Blood; 2019 Sep; 134(12):924-934. PubMed ID: 31292117
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal.
Valentini CG; Chiusolo P; Bianchi M; Metafuni E; Orlando N; Giammarco S; Bacigalupo A; Sica S; Teofili L
Cytotherapy; 2021 Jul; 23(7):635-640. PubMed ID: 33423867
[TBL] [Abstract][Full Text] [Related]
14. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
Tsai SB; Rhodes J; Liu H; Shore T; Bishop M; Cushing MM; Gergis U; Godley L; Kline J; Larson RA; Mayer S; Odenike O; Stock W; Wickrema A; van Besien K; Artz AS
Biol Blood Marrow Transplant; 2018 May; 24(5):997-1004. PubMed ID: 29288821
[TBL] [Abstract][Full Text] [Related]
15. Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
Segal E; Martens M; Wang HL; Brazauskas R; Weisdorf D; Sandmaier BM; Khoury HJ; de Lima M; Saber W
Cancer; 2017 Sep; 123(17):3346-3355. PubMed ID: 28452054
[TBL] [Abstract][Full Text] [Related]
16. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
17. Unrelated donor stem cell transplantation: the role of the National Marrow Donor Program.
Karanes C; Confer D; Walker T; Askren A; Keller C
Oncology (Williston Park); 2003 Aug; 17(8):1036-8, 1043-4, 1164-7. PubMed ID: 12966671
[TBL] [Abstract][Full Text] [Related]
18. Identification of a 10/10 matched donor for patients with an uncommon haplotype is unlikely.
Olson JA; Gibbens Y; Tram K; Kempenich J; Novakovich J; Buck K; Dehn J
HLA; 2017 Feb; 89(2):77-81. PubMed ID: 28102042
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical
Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
[TBL] [Abstract][Full Text] [Related]
20. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
